ArticleBMC cancer2026
The role of age and antibodies in central regional lymph node metastases of papillary thyroid carcinoma combined with hashimoto's thyroiditis.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe coexistence of Hashimoto thyroiditis (HT) and papillary thyroid carcinoma (PTC) is increasing year by year, and the role of age, thyroglobulin antibodies (TgAb), and thyroid peroxidase antibodies (TPOAb) in central neck lymph node metastasis (CLNM) in PTC patients with HT is still controversial.
methodsIn this study, we retrospectively collected information about 540 PTC patients with HT, explored the risk prediction of CLNM by related factors through univariate, multivariate logistic regression and restricted cubic spline (RCS) plots.
resultsIn univariate logistic analysis, age, gender, no history of hypertension, ultrasound image characteristics (largest diameter of the suspicious thyroid nodule, calcification of the suspicious thyroid nodule, suspicious lymph nodes), thyroid-related antibodies (TgAb, TPOAb) were statistically significant in CLNM in PTC patients with HT (PTC-HT) significance (P < 0.05) ; after adjustment for many variables, age, TgAb, and TPOAb were significantly associated with CLNM. Age < 45 years and TgAb positivity were risk factors for CLNM in PTC patients combined with HT, and TPOAb positivity was a protective factor for CLNM in PTC patients with HT. Between age and TgAb, the risk of CLNM was greatest at age < 45 years combined with TgAb positivity (P < 0.001, OR = 5.771, 95% CI 2.690-12.383); between age and TPOAb, the risk of CLNM metastasis was greatest when age < 45 years combined with negative TPOAb (P < 0.001, OR = 4.856, 95% CI 2.732-8.630) ; between TgAb and TPOAb, the risk of CLNM metastasis was greatest when TgAb positivity combined with negative TPOAb (P = 0.002, OR = 2596, 95% CI 1.430-4.713).
conclusionsYounger age and TgAb positivity are significant risk factors for CLNM in PTC patients with HT, and TPOAb positivity plays a protective role, therefore, age, TgAb and TPOAb have important predictive value. Patients aged < 45 years, with TgAb positivity and TPOAb negativity should not only pay attention to adequately assessing the metastatic status of CLNM preoperatively and formulating a suitable surgical scope, but also to monitoring antibody levels for follow-up after the operation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.